78 related articles for article (PubMed ID: 15612979)
1. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
Oberbauer R; Segoloni G; Campistol JM; Kreis H; Mota A; Lawen J; Russ G; Grinyó JM; Stallone G; Hartmann A; Pinto JR; Chapman J; Burke JT; Brault Y; Neylan JF;
Transpl Int; 2005 Jan; 18(1):22-8. PubMed ID: 15612979
[TBL] [Abstract][Full Text] [Related]
2. Optimizing the therapeutic window of sirolimus by monitoring blood concentration for the treatment of immune thrombocytopenia.
Zhang Y; Quan Y; Wang D; Cassady K; Zou W; Xiong J; Yao H; Deng X; Wang P; Yang S; Zhang X; Feng Y
Platelets; 2023 Dec; 34(1):2277831. PubMed ID: 38050853
[TBL] [Abstract][Full Text] [Related]
3. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of sirolimus therapy with early cyclosporin withdrawal vs. long-term cyclosporin therapy in Australia.
Gordois A; Nobes M; Toohey M; Russ G
Clin Transplant; 2006; 20(4):526-36. PubMed ID: 16842533
[TBL] [Abstract][Full Text] [Related]
5. Belatacept in renal transplantation in comparison to tacrolimus and molecular understanding of resistance pattern: Meta-analysis and systematic review.
Kumar J; Reccia I; Virdis F; Podda M; Sharma AK; Halawa A
World J Transplant; 2021 Mar; 11(3):70-86. PubMed ID: 33816147
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Conversion from a Calcineurin Inhibitor to Sirolimus on Skin Cancer Reduction in Post-renal Transplantation Patients.
Smith A; Niu W; Desai A
Cureus; 2017 Aug; 9(8):e1564. PubMed ID: 29057176
[TBL] [Abstract][Full Text] [Related]
7. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.
Karpe KM; Talaulikar GS; Walters GD
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD006750. PubMed ID: 28730648
[TBL] [Abstract][Full Text] [Related]
8. Analysis of liver function test abnormalities in kidney transplant recipients: 7 year experience.
Dizdar OS; Ersoy A; Aksoy S; Ozel Coskun BD; Yildiz A
Pak J Med Sci; 2016; 32(6):1330-1335. PubMed ID: 28083020
[TBL] [Abstract][Full Text] [Related]
9. Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.
Fantus D; Rogers NM; Grahammer F; Huber TB; Thomson AW
Nat Rev Nephrol; 2016 Oct; 12(10):587-609. PubMed ID: 27477490
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus conversion efficacy for graft function improvement and histopathology in renal recipients with mild to moderate renal insufficiency.
Joo DJ; Yang CW; Jeong HJ; Lim BJ; Huh KH; Chung BH; Choi YJ; Kang SW; Kim YS
J Korean Med Sci; 2014 Aug; 29(8):1069-76. PubMed ID: 25120315
[TBL] [Abstract][Full Text] [Related]
11. N-Octanoyl dopamine transiently inhibits T cell proliferation via G1 cell-cycle arrest and inhibition of redox-dependent transcription factors.
Wedel J; Hottenrott MC; Stamellou E; Breedijk A; Tsagogiorgas C; Hillebrands JL; Yard BA
J Leukoc Biol; 2014 Sep; 96(3):453-62. PubMed ID: 24929005
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and risk factors for early chronic allograft nephropathy in a live related renal transplant program.
Khan H; Mubarak M; Aziz T; Ahmed E; Fazal Akhter S; Kazi J; Aa Naqvi S; Ah Rizvi S
J Nephropathol; 2014; 3(2):69-79. PubMed ID: 24772400
[TBL] [Abstract][Full Text] [Related]
13. Optimising the use of mTOR inhibitors in renal transplantation.
Russ GR
Transplant Res; 2013 Nov; 2(Suppl 1):S4. PubMed ID: 24565283
[TBL] [Abstract][Full Text] [Related]
14. Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?
Gatault P; Lebranchu Y
Transplant Res; 2013 Nov; 2(Suppl 1):S3. PubMed ID: 24565231
[TBL] [Abstract][Full Text] [Related]
15. Is it time to give up with calcineurin inhibitors in kidney transplantation?
Salvadori M; Bertoni E
World J Transplant; 2013 Jun; 3(2):7-25. PubMed ID: 24175203
[TBL] [Abstract][Full Text] [Related]
16. Immunosenescence and organ transplantation.
Heinbokel T; Elkhal A; Liu G; Edtinger K; Tullius SG
Transplant Rev (Orlando); 2013 Jul; 27(3):65-75. PubMed ID: 23639337
[TBL] [Abstract][Full Text] [Related]
17. A prospective, multinational pharmacoepidemiological study of clinical conversion to sirolimus immunosuppression after renal transplantation.
Kasiske BL; Nashan B; Del Carmen Rial M; Raffaele P; Russ G; Campistol J; Pescovitz MD; Keown PA
J Transplant; 2012; 2012():107180. PubMed ID: 22934151
[TBL] [Abstract][Full Text] [Related]
18. Key Features of the Intragraft Microenvironment that Determine Long-Term Survival Following Transplantation.
Bruneau S; Woda CB; Daly KP; Boneschansker L; Jain NG; Kochupurakkal N; Contreras AG; Seto T; Briscoe DM
Front Immunol; 2012; 3():54. PubMed ID: 22566935
[TBL] [Abstract][Full Text] [Related]
19. Steroid or tacrolimus withdrawal in renal transplant recipients using sirolimus.
de Sandes Freitas TV; Harada KM; Felipe CR; Galante NZ; Sampaio EL; Ikehara E; Alfieri F; Tedesco-Silva Júnior H; Medina-Pestana JO
Int Urol Nephrol; 2011 Dec; 43(4):1221-8. PubMed ID: 21761129
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up.
Frimat L; Cassuto-Viguier E; Provôt F; Rostaing L; Charpentier B; Akposso K; Moal MC; Lang P; Glotz D; Caillard S; Ducloux D; Pouteil-Noble C; Girardot-Seguin S; Kessler M
J Transplant; 2010; 2010():. PubMed ID: 20706667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
